title: Proteomic analysis of pancreatic secretory trypsin inhibitor/tumor-associated trypsin inhibitor from urine of patients with pancreatitis or prostate cancer.
abstract: The development of proteomic methods, especially mass spectrometry, has brought new possibilities to tumor marker research. Pancreatic secretory trypsin inhibitor (PSTI), a common known biomarker for various malignancies, occurs on genetic variants that we are able to detect at the protein level with proteomic techniques using immunoaffinity capture prior to liquid chromatography-mass spectrometry (LC-MS). We also show that PSTI can be detected in urine from cancer patients using a two-step peptide enrichment technique and LC-MS. These results show that tumor-associated peptides can be detected in urine by proteomic techniques.
authors.affiliation: Department of Clinical Medicine, Division of Clinical Chemistry, Biomedicum, University of Helsinki, Helsinki, Finland.
authors.forename: Leena
authors.initials: L
authors.lastname: Valmu
authors.forename: Suvi
authors.initials: S
authors.lastname: Ravela
authors.forename: Ulf-Håkan
authors.initials: UH
authors.lastname: Stenman
mesh_terms: D053000:Analytic Sample Preparation Methods; D002352:Carrier Proteins / Q000276:immunology / Q000652:urine*; D002853:Chromatography, Liquid; D006801:Humans; D008297:Male; D010195:Pancreatitis / Q000652:urine*; D010455:Peptides / Q000652:urine; D011471:Prostatic Neoplasms / Q000652:urine*; D040901:Proteomics / Q000379:methods*; D021241:Spectrometry, Mass, Electrospray Ionization; D014359:Trypsin Inhibitor, Kazal Pancreatic; D014361:Trypsin Inhibitors / Q000276:immunology / Q000652:urine*; D016482:Urinalysis / Q000379:methods*
chemical_list: D002352:Carrier Proteins; D010455:Peptides; C486642:SPINK1 protein, human; D014361:Trypsin Inhibitors; D014359:Trypsin Inhibitor, Kazal Pancreatic